Viral Vector Production (Research-use) Market (By Type: Adeno-associated virus, Lentivirus, Adenovirus, Retrovirus, Others; By Application: Cell & Gene Therapy Development, Vaccine Development, Biopharmaceutical and Pharmaceutical Discovery, Biomedical Research; By Workflow: Upstream Processing, Downstream Processing; By End-use: Pharmaceutical and Biopharmaceutical Companies, Research Institutes) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 2021 - 2030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Viral Vector Production (Research-use) Market, By Vector Type

7.1.  Viral Vector Production (Research-use) Market, by Vector Type, 2021-2030

7.1.1.    Adeno-associated virus (AAV)

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Lentivirus

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Adenovirus

7.1.3.1.        Market Revenue and Forecast (2017-2030)

7.1.4.    Retrovirus

7.1.4.1.        Market Revenue and Forecast (2017-2030)

7.1.5.    Others

7.1.5.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Viral Vector Production (Research-use) Market, By Application

8.1.  Viral Vector Production (Research-use) Market, by Application, 2021-2030

8.1.1.    Cell & Gene Therapy Development

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Vaccine Development

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Biopharmaceutical and Pharmaceutical Discovery

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Biomedical Research

8.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Viral Vector Production (Research-use) Market, By Workflow

9.1.  Viral Vector Production (Research-use) Market, by Workflow, 2021-2030

9.1.1.    Upstream Processing

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Downstream Processing

9.1.2.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Viral Vector Production (Research-use) Market, By End-use

10.1.        Viral Vector Production (Research-use) Market, by End-use, 2021-2030

10.1.1.  Pharmaceutical and Biopharmaceutical Companies

10.1.1.1.      Market Revenue and Forecast (2017-2030)

10.1.2.  Research Institutes

10.1.2.1.      Market Revenue and Forecast (2017-2030)

Chapter 11.      Global Viral Vector Production (Research-use) Market, Regional Estimates and Trend Forecast

11.1.        North America

11.1.1.  Market Revenue and Forecast, by Vector Type (2017-2030)

11.1.2.  Market Revenue and Forecast, by Application (2017-2030)

11.1.3.  Market Revenue and Forecast, by Workflow (2017-2030)

11.1.4.  Market Revenue and Forecast, by End-use (2017-2030)

11.1.5.  U.S.

11.1.5.1.      Market Revenue and Forecast, by Vector Type (2017-2030)

11.1.5.2.      Market Revenue and Forecast, by Application (2017-2030)

11.1.5.3.      Market Revenue and Forecast, by Workflow (2017-2030)

11.1.5.4.      Market Revenue and Forecast, by End-use (2017-2030)

11.1.6.  Rest of North America

11.1.6.1.      Market Revenue and Forecast, by Vector Type (2017-2030)

11.1.6.2.      Market Revenue and Forecast, by Application (2017-2030)

11.1.6.3.      Market Revenue and Forecast, by Workflow (2017-2030)

11.1.6.4.      Market Revenue and Forecast, by End-use (2017-2030)

11.2.        Europe

11.2.1.  Market Revenue and Forecast, by Vector Type (2017-2030)

11.2.2.  Market Revenue and Forecast, by Application (2017-2030)

11.2.3.  Market Revenue and Forecast, by Workflow (2017-2030)

11.2.4.  Market Revenue and Forecast, by End-use (2017-2030)

11.2.5.  UK

11.2.5.1.      Market Revenue and Forecast, by Vector Type (2017-2030)

11.2.5.2.      Market Revenue and Forecast, by Application (2017-2030)

11.2.5.3.      Market Revenue and Forecast, by Workflow (2017-2030)

11.2.5.4.      Market Revenue and Forecast, by End-use (2017-2030)

11.2.6.  Germany

11.2.6.1.      Market Revenue and Forecast, by Vector Type (2017-2030)

11.2.6.2.      Market Revenue and Forecast, by Application (2017-2030)

11.2.6.3.      Market Revenue and Forecast, by Workflow (2017-2030)

11.2.6.4.      Market Revenue and Forecast, by End-use (2017-2030)

11.2.7.  France

11.2.7.1.      Market Revenue and Forecast, by Vector Type (2017-2030)

11.2.7.2.      Market Revenue and Forecast, by Application (2017-2030)

11.2.7.3.      Market Revenue and Forecast, by Workflow (2017-2030)

11.2.7.4.      Market Revenue and Forecast, by End-use (2017-2030)

11.2.8.  Rest of Europe

11.2.8.1.      Market Revenue and Forecast, by Vector Type (2017-2030)

11.2.8.2.      Market Revenue and Forecast, by Application (2017-2030)

11.2.8.3.      Market Revenue and Forecast, by Workflow (2017-2030)

11.2.8.4.      Market Revenue and Forecast, by End-use (2017-2030)

11.3.        APAC

11.3.1.  Market Revenue and Forecast, by Vector Type (2017-2030)

11.3.2.  Market Revenue and Forecast, by Application (2017-2030)

11.3.3.  Market Revenue and Forecast, by Workflow (2017-2030)

11.3.4.  Market Revenue and Forecast, by End-use (2017-2030)

11.3.5.  India

11.3.5.1.      Market Revenue and Forecast, by Vector Type (2017-2030)

11.3.5.2.      Market Revenue and Forecast, by Application (2017-2030)

11.3.5.3.      Market Revenue and Forecast, by Workflow (2017-2030)

11.3.5.4.      Market Revenue and Forecast, by End-use (2017-2030)

11.3.6.  China

11.3.6.1.      Market Revenue and Forecast, by Vector Type (2017-2030)

11.3.6.2.      Market Revenue and Forecast, by Application (2017-2030)

11.3.6.3.      Market Revenue and Forecast, by Workflow (2017-2030)

11.3.6.4.      Market Revenue and Forecast, by End-use (2017-2030)

11.3.7.  Japan

11.3.7.1.      Market Revenue and Forecast, by Vector Type (2017-2030)

11.3.7.2.      Market Revenue and Forecast, by Application (2017-2030)

11.3.7.3.      Market Revenue and Forecast, by Workflow (2017-2030)

11.3.7.4.      Market Revenue and Forecast, by End-use (2017-2030)

11.3.8.  Rest of APAC

11.3.8.1.      Market Revenue and Forecast, by Vector Type (2017-2030)

11.3.8.2.      Market Revenue and Forecast, by Application (2017-2030)

11.3.8.3.      Market Revenue and Forecast, by Workflow (2017-2030)

11.3.8.4.      Market Revenue and Forecast, by End-use (2017-2030)

11.4.        MEA

11.4.1.  Market Revenue and Forecast, by Vector Type (2017-2030)

11.4.2.  Market Revenue and Forecast, by Application (2017-2030)

11.4.3.  Market Revenue and Forecast, by Workflow (2017-2030)

11.4.4.  Market Revenue and Forecast, by End-use (2017-2030)

11.4.5.  GCC

11.4.5.1.      Market Revenue and Forecast, by Vector Type (2017-2030)

11.4.5.2.      Market Revenue and Forecast, by Application (2017-2030)

11.4.5.3.      Market Revenue and Forecast, by Workflow (2017-2030)

11.4.5.4.      Market Revenue and Forecast, by End-use (2017-2030)

11.4.6.  North Africa

11.4.6.1.      Market Revenue and Forecast, by Vector Type (2017-2030)

11.4.6.2.      Market Revenue and Forecast, by Application (2017-2030)

11.4.6.3.      Market Revenue and Forecast, by Workflow (2017-2030)

11.4.6.4.      Market Revenue and Forecast, by End-use (2017-2030)

11.4.7.  South Africa

11.4.7.1.      Market Revenue and Forecast, by Vector Type (2017-2030)

11.4.7.2.      Market Revenue and Forecast, by Application (2017-2030)

11.4.7.3.      Market Revenue and Forecast, by Workflow (2017-2030)

11.4.7.4.      Market Revenue and Forecast, by End-use (2017-2030)

11.4.8.  Rest of MEA

11.4.8.1.      Market Revenue and Forecast, by Vector Type (2017-2030)

11.4.8.2.      Market Revenue and Forecast, by Application (2017-2030)

11.4.8.3.      Market Revenue and Forecast, by Workflow (2017-2030)

11.4.8.4.      Market Revenue and Forecast, by End-use (2017-2030)

11.5.        Latin America

11.5.1.  Market Revenue and Forecast, by Vector Type (2017-2030)

11.5.2.  Market Revenue and Forecast, by Application (2017-2030)

11.5.3.  Market Revenue and Forecast, by Workflow (2017-2030)

11.5.4.  Market Revenue and Forecast, by End-use (2017-2030)

11.5.5.  Brazil

11.5.5.1.      Market Revenue and Forecast, by Vector Type (2017-2030)

11.5.5.2.      Market Revenue and Forecast, by Application (2017-2030)

11.5.5.3.      Market Revenue and Forecast, by Workflow (2017-2030)

11.5.5.4.      Market Revenue and Forecast, by End-use (2017-2030)

11.5.6.  Rest of LATAM

11.5.6.1.      Market Revenue and Forecast, by Vector Type (2017-2030)

11.5.6.2.      Market Revenue and Forecast, by Application (2017-2030)

11.5.6.3.      Market Revenue and Forecast, by Workflow (2017-2030)

11.5.6.4.      Market Revenue and Forecast, by End-use (2017-2030)

Chapter 12.  Company Profiles

12.1.              Merck KGaA

12.1.1.  Company Overview

12.1.2.  Product Offerings

12.1.3.  Financial Performance

12.1.4.  Recent Initiatives

12.2.              Lonza

12.2.1.  Company Overview

12.2.2.  Product Offerings

12.2.3.  Financial Performance

12.2.4.  Recent Initiatives

12.3.              FUJIFILM Diosynth Biotechnologies U.S.A., Inc.

12.3.1.  Company Overview

12.3.2.  Product Offerings

12.3.3.  Financial Performance

12.3.4.  Recent Initiatives

12.4.              Cobra Biologics Ltd.

12.4.1.  Company Overview

12.4.2.  Product Offerings

12.4.3.  Financial Performance

12.4.4.  Recent Initiatives

12.5.              Thermo Fisher Scientific

12.5.1.  Company Overview

12.5.2.  Product Offerings

12.5.3.  Financial Performance

12.5.4.  Recent Initiatives

12.6.              Waisman Biomanufacturing

12.6.1.  Company Overview

12.6.2.  Product Offerings

12.6.3.  Financial Performance

12.6.4.  Recent Initiatives

12.7.              Genezen

12.7.1.  Company Overview

12.7.2.  Product Offerings

12.7.3.  Financial Performance

12.7.4.  Recent Initiatives

12.8.              YPOSKESI

12.8.1.  Company Overview

12.8.2.  Product Offerings

12.8.3.  Financial Performance

12.8.4.  Recent Initiatives

12.9.              Advanced BioScience Laboratories, Inc. (ABL, Inc.)

12.9.1.  Company Overview

12.9.2.  Product Offerings

12.9.3.  Financial Performance

12.9.4.  Recent Initiatives

12.10.           Novasep Holding S.A.S

12.10.1.               Company Overview

12.10.2.               Product Offerings

12.10.3.               Financial Performance

12.10.4.               Recent Initiatives

12.11.           Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.)

12.11.1.               Company Overview

12.11.2.               Product Offerings

12.11.3.               Financial Performance

12.11.4.               Recent Initiatives

12.12.           Vigene Biosciences, Inc.

12.12.1.               Company Overview

12.12.2.               Product Offerings

12.12.3.               Financial Performance

12.12.4.               Recent Initiatives

12.13.           General Electric Company (GE Healthcare)

12.13.1.               Company Overview

12.13.2.               Product Offerings

12.13.3.               Financial Performance

12.13.4.               Recent Initiatives

12.14.           CEVEC Pharmaceuticals GmbH

12.14.1.               Company Overview

12.14.2.               Product Offerings

12.14.3.               Financial Performance

12.14.4.               Recent Initiatives

12.15.           Batavia Biosciences B.V.

12.15.1.               Company Overview

12.15.2.               Product Offerings

12.15.3.               Financial Performance

12.15.4.               Recent Initiatives

12.16.           Biovion oy

12.16.1.               Company Overview

12.16.2.               Product Offerings

12.16.3.               Financial Performance

12.16.4.               Recent Initiatives

12.17.           Wuxi AppTec Co., Ltd.

12.17.1.               Company Overview

12.17.2.               Product Offerings

12.17.3.               Financial Performance

12.17.4.               Recent Initiatives

Chapter 13.  Research Methodology

13.1.              Primary Research

13.2.              Secondary Research

13.3.              Assumptions

Chapter 14.  Appendix

14.1.              About Us

Glossary of Terms